argenx SE (FRA:1AEA)
Germany · Delayed Price · Currency is EUR | Market Cap | 48.78B +69.0% |
| Revenue (ttm) | 4.11B +79.4% |
| Net Income | 1.29B +39.9% |
| EPS | 19.51 +41.1% |
| Shares Out | n/a |
| PE Ratio | 37.77 |
| Forward PE | 30.40 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 765.00 |
| Previous Close | 770.00 |
| Day's Range | 765.00 - 775.00 |
| 52-Week Range | 454.00 - 810.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 23, 2026 |
About argenx SE
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave’s disease, myositis, Sjögren’s disease, system... [Read more]
Financial Performance
In 2025, argenx SE's revenue was $4.24 billion, an increase of 88.44% compared to the previous year's $2.25 billion. Earnings were $1.29 billion, an increase of 55.10%.
Financial numbers in USD Financial StatementsNews
ARGX Reiterates by HC Wainwright & Co. -- Price Target Maintained at $940
ARGX Reiterates by HC Wainwright & Co. -- Price Target Maintained at $940
ARGX Maintained by Morgan Stanley -- Price Target Raised to $1180
ARGX Maintained by Morgan Stanley -- Price Target Raised to $1180
Can Argenx Retake Its Record High — And A Buy Point — On A New Vyvgart Strategy?
Argenx stock reversed course Wednesday, bumping above its 21-day line, as investors digested its myositis-focused R&D Day.
Argenx price target raised to $1,180 from $1,170 at Morgan Stanley
Morgan Stanley analyst Sean Laaman raised the firm’s price target on Argenx (ARGX) to $1,180 from $1,170 and keeps an Overweight rating on the shares. Argenx hosted an autoimmune myositis…
argenx SE Transcript: Status update
Autoimmune myositis, particularly IMNM and DM, are prioritized for label expansion based on strong biology, urgent unmet need, and robust phase II data. Regulatory and commercial strategies are aligned for rapid approval and market entry, with phase III data expected in Q3. IMNM and DM are seen as multi-blockbuster opportunities, supporting long-term growth and leadership in immunology.
argenx Eyes More VYVGART Growth as Pipeline Catalysts Near
Executives at argenex NASDAQ: ARGX told investors at a Goldman Sachs healthcare event that they continue to see meaningful growth opportunities for VYVGART across myasthenia gravis and chronic inflamm...
argenx SE Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
VYVGART continues to drive strong growth in MG and CIDP, with significant market expansion expected through new indications and self-injection formulation. Multiple late-stage pipeline readouts are anticipated in H2, including myositis and next-gen FcRn assets, while business development remains focused on innovation and partnerships. OpEx growth is guided at 30% with improving margins expected.
argenx Touts VYVGART Growth, 50,000-Patient Goal at William Blair Conference
argenx NASDAQ: ARGX Chief Financial Officer Karl Gubitz told investors at the 46th Annual William Blair Growth Stock Conference that the biotechnology company remains focused on revenue growth, profit...
ARGX Reiterated by Wedbush -- Maintains Price Target at $1000
ARGX Reiterated by Wedbush -- Maintains Price Target at $1000
argenx SE Transcript: 46th Annual William Blair Growth Stock Conference
The company reported sustained revenue and profit growth, driven by its lead asset and differentiated delivery options. Ambitious 2030 goals include expanding to 50,000 patients and 10 indications, with a robust pipeline and disciplined pricing strategy supporting long-term growth.
ArgenX Reports Phase 2 Extension Results For Efgartigimod In Treating Autoimmune Diseases
(RTTNews) - Argenx SE (ARGX), a commercial-stage biopharmaceutical company, announced new clinical data from Phase 2 extension studies for efgartigimod in the treatment of myositis and Sjogren's disea...
Argenx (ARGX) Presents New Vyvgart Data at EULAR 2026 Congress
Argenx (ARGX) Presents New Vyvgart Data at EULAR 2026 Congress
Argenx presents new Vyvgart data at EULAR
Argenx (ARGX) announced the presentation of new data evaluating Vyvgart across autoimmune rheumatic diseases, including myositis and Sjogren’s disease, to be presented at the European Alliance of Asso...
argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
ALKIVIA+ data in myositis indicate efgartigimod provides sustained, clinically meaningful improvements and consistent safety RHO+ data in Sjogren's disease indicate maintenance of response following s...
ARGX Maintained by Wells Fargo -- Price Target Raised to $1291
ARGX Maintained by Wells Fargo -- Price Target Raised to $1291
Argenx price target raised to $1,291 from $1,260 at Wells Fargo
Wells Fargo raised the firm’s price target on Argenx (ARGX) to $1,291 from $1,260 and keeps an Overweight rating on the shares. The firm remains constructive into Vyvgart’s Phase 3…
Argenx price target raised to $1,255 from $1,222 at Stifel
Stifel analyst Alex Thompson raised the firm’s price target on Argenx (ARGX) to $1,255 from $1,222 and keeps a Buy rating on the shares. Phase 3 data for the ALKIVIA…
argenx to Host Myositis R&D Webinar on June 23, 2026
May 28, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today anno...
ARGX Maintained by Evercore ISI Group -- Price Target Raised to $1059
ARGX Maintained by Evercore ISI Group -- Price Target Raised to $1059
Argenx price target raised to $1,059 from $1,007 at Evercore ISI
Evercore ISI analyst Gavin Clark-Gartner raised the firm’s price target on Argenx (ARGX) to $1,059 from $1,007 and keeps an Outperform rating on the shares.
argenx SE Transcript: Bank of America Global Healthcare Conference 2026
FDA leadership turnover and regulatory uncertainty dominate the policy landscape, with drug pricing reforms and MFN agreements creating long-term industry vulnerabilities. China’s rise in biopharma is accelerating, prompting bipartisan concern but limited immediate legislative action. Expect regulatory focus and oversight to increase post-election, with major reforms unlikely this year.
Argenx price target raised to $1,016 from $1,013 at BofA
BofA analyst Tazeen Ahmad raised the firm’s price target on Argenx (ARGX) to $1,016 from $1,013 and keeps a Buy rating on the shares. Approval of Vyvgart and Vyvgart Hytrulo…
Argenx: FDA approves label expansion for Vyvgart, Vvygart Hytrulo
Argenx (ARGX) announced the U.S. FDA approved a label expansion for Vyvgart and Vyvgart Hytrulo for the treatment of adult patients with generalized myasthenia gravis. The approved supplemental Biolog...
argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
VYVGART and VYVGART Hytrulo are the first and only approved treatments for all serotypes of adult patients living with gMG – anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and tr...
Argenx price target lowered to $1,170 from $1,230 at Morgan Stanley
Morgan Stanley analyst Sean Laaman lowered the firm’s price target on Argenx (ARGX) to $1,170 from $1,230 and keeps an Overweight rating on the shares.